Compare YSG & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | VYGR |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 236.0M |
| IPO Year | 2020 | 2015 |
| Metric | YSG | VYGR |
|---|---|---|
| Price | $3.02 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 159.7K | ★ 900.2K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $23.08 | $33.19 |
| Revenue Next Year | $9.45 | $14.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $2.65 |
| 52 Week High | $11.04 | $5.55 |
| Indicator | YSG | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 48.30 |
| Support Level | $2.87 | $3.72 |
| Resistance Level | $4.39 | $4.30 |
| Average True Range (ATR) | 0.25 | 0.21 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 9.52 | 51.75 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.